Keros Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	287.42	559.93	331.15	279.05	230.04
Cash & Short-Term Investments	287.42	559.93	331.15	279.05	230.04
Cash Growth	-48.67%	69.09%	18.67%	21.30%	-13.48%
Accounts Receivable	3.57	2.74	0.14	-	18
Other Receivables	2.25	-	-	-	-
Total Trade Receivables	5.82	2.74	0.14	-	18
Other Current Assets	22.2	26.22	16	6.72	3.4
Total Current Assets	315.43	588.89	347.29	285.77	251.44
Net Property, Plant & Equipment	21.14	23.49	19.47	17.57	2.4
Other Long-Term Assets	1.45	3.51	3.26	3.45	1.41
Total Assets	338.02	615.89	370.03	306.78	255.25
Accounts Payable	1.97	4.6	5.45	3.34	3.65
Accrued Expenses	16.04	20.87	17.92	12.75	7.34
Current Portion of Leases	2.41	1.98	1.01	0.46	0.86
Total Current Liabilities	20.41	27.45	24.37	16.55	11.85
Long-Term Leases	14.48	16.88	13.44	12.81	0.23
Total Long-Term Liabilities	14.48	16.88	13.44	12.81	0.23
Total Liabilities	34.89	44.33	37.81	29.36	12.08
Common Stock	0	0	0	0	0
Treasury Stock	-384.56	-	-	-	-
Additional Paid-in Capital	1,169	1,140	713.64	505.86	366.93
Retained Earnings	-481.77	-568.78	-381.43	-228.43	-123.76
Shareholders' Equity	303.13	571.55	332.21	277.42	243.17
Total Liabilities & Equity	338.02	615.89	370.03	306.78	255.25
Total Debt	16.88	18.86	14.44	13.27	1.09
Net Cash (Debt)	270.53	541.07	316.7	265.78	228.95
Net Cash Growth	-50.00%	70.84%	19.16%	16.09%	-13.60%
Net Cash Per Share	7.15	14.45	10.76	10.53	9.81
Book Value	303.13	571.55	332.21	277.42	243.17
Book Value Per Share	8.01	15.27	11.28	10.99	10.42
Tangible Book Value	303.13	571.55	332.21	277.42	243.17
Tangible Book Value Per Share	8.01	15.27	11.28	10.99	10.42

Updated Mar 4, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q